Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Insmed Incorporated, Kymera Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Insmed Incorporated, Kymera Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Insmed Incorporated, Kymera Therapeutics and Inc.

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Latest Biotechnology and Insmed Incorporated, Kymera Therapeutics, Inc. Stock News

As of September 11, 2026, Insmed Incorporated had a $28.3 billion market capitalization, compared to the Biotechnology median of $269.3 million. Insmed Incorporated’s stock is NA in 2026, NA in the previous five trading days and down 11.3% in the past year.

Currently, Insmed Incorporated does not have a price-earnings ratio. Insmed Incorporated’s trailing 12-month revenue is $1.1 billion with a -76.9% net profit margin. Year-over-year quarterly sales growth most recently was 296.2%. Analysts expect adjusted earnings to reach $-1.554 per share for the current fiscal year. Insmed Incorporated does not currently pay a dividend.

Currently, Kymera Therapeutics, Inc. does not have a price-earnings ratio. Kymera Therapeutics, Inc.’s trailing 12-month revenue is $105.0 million with a -285.3% net profit margin. Year-over-year quarterly sales growth most recently was 465.2%. Analysts expect adjusted earnings to reach $-3.815 per share for the current fiscal year. Kymera Therapeutics, Inc. does not currently pay a dividend.

How We Compare Insmed Incorporated, Kymera Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Insmed Incorporated, Kymera Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Insmed Incorporated, Kymera Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
Insmed Incorporated	INSM	F
Kymera Therapeutics, Inc.	KYMR	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Insmed Incorporated has a Value Score of 1, which is Ultra Expensive. Kymera Therapeutics, Inc. has a Value Score of 2, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Insmed Incorporated, Kymera Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Insmed Incorporated, Kymera Therapeutics or Inc. is the better investment when it comes to value.

Insmed Incorporated, Kymera Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Insmed Incorporated	INSM	B
Kymera Therapeutics, Inc.	KYMR	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Insmed Incorporated has a Momentum Score of 70, which is Strong. Kymera Therapeutics, Inc. has a Momentum Score of 95, which is Very Strong.

The Momentum Grade Winner: Kymera Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Kymera Therapeutics, Inc. is considered to have stronger momentum compared to Insmed Incorporated. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Kymera Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Insmed Incorporated, Kymera Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Insmed Incorporated	INSM	C
Kymera Therapeutics, Inc.	KYMR	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Insmed Incorporated has a Earnings Estimate Score of 54, which is Neutral. Kymera Therapeutics, Inc. has a Earnings Estimate Score of 32, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Insmed Incorporated, Kymera Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Insmed Incorporated, Kymera Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other Insmed Incorporated, Kymera Therapeutics and Inc. Grades

In addition to Value, Estimate Revisions and Momentum, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Insmed Incorporated, Kymera Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Insmed Incorporated, Kymera Therapeutics or Inc. Stock?

Overall, Insmed Incorporated stock has a Value Score of 1, Momentum Score of 70 and Estimate Revisions Score of 54.

Kymera Therapeutics, Inc. stock has a Value Score of 2, Momentum Score of 95 and Estimate Revisions Score of 32.

Comparing Insmed Incorporated, Kymera Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.